(Q42153256)

English

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Viktor H. Koelzer

1

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Giuseppe V Masucci

5

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

author name string

Heather Dawson

2

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Emilia Andersson

3

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Eva Karamitopoulou

4

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Alessandro Lugli

6

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Inti Zlobec

7

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

publication date

4 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Translational Research

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

166

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

207-217

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Dependence of peptide binding by MHC class I molecules on their interaction with TAP.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Generation of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

The spatio-temporal expression of MHC class I molecules during human hippocampal formation development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Two-marker protein profile predicts poor prognosis in patients with early rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

The immune contexture in human tumours: impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

K-ras mutations (codon 12) are not involved in down-regulation of MHC class-I genes in colon carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.02.008

7 January 2021

Identifiers

10.1016/J.TRSL.2015.02.008

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42153256&oldid=1934866692"